PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.62%
Negative EBIT growth while AGEN is at 30.25%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-201.62%
Negative operating income growth while AGEN is at 30.25%. Joel Greenblatt would press for urgent turnaround measures.
-128.59%
Negative net income growth while AGEN stands at 148.11%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-127.78%
Negative EPS growth while AGEN is at 147.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-127.78%
Negative diluted EPS growth while AGEN is at 147.47%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.70%
OCF growth 1.25-1.5x AGEN's 33.87%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
37.70%
FCF growth 1.25-1.5x AGEN's 33.73%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.48%
10Y OCF/share CAGR under 50% of AGEN's 67.56%. Michael Burry would worry about a persistent underperformance in cash creation.
24.48%
Below 50% of AGEN's 77.11%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
24.48%
3Y OCF/share CAGR under 50% of AGEN's 73.92%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
9.10%
Below 50% of AGEN's 106.30%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
9.10%
Below 50% of AGEN's 118.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
9.10%
Below 50% of AGEN's 120.38%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-301.87%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-301.87%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-301.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-11.47%
We have a declining book value while AGEN shows 20.22%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
6.41%
We have some new debt while AGEN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
186.72%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.